Newtown-based Meridian Bioscience Inc. on Monday said its European subsidiary had reached a distribution agreement with ScheBo Biotech AG to market the German firm's pancreatic diagnostic test.

        Meridian Bioscience Europe Srl. will market the test in Europe. The test detects a key chemical insufficiency that can indicate pancreatitis, cystic fibrosis, pancreatic cancer and diabetes mellitus.

        The company says pancreatic disease affects 150 million people worldwide, making early detection of potential problems critical.

        It will be offered in conjunction with a unique test for the early detection of tumor metastasis and chemotherapy follow-up.

        Meridian's stock was up 22 cents on the news, closing at $5.22 Monday.

        Have a tip about a Tristate company that should be included in our Buzz? Call 768-8147 or e-mail business@enquirer.com.

Synchrony software firm sold
Casinos revenue dropped in September
Internet industry backs filtering system
War bonds near approval
Pratt & Whitney takes show on road
Duramed posts record income
Valvoline helps push Ashland to record year
Oh, Big Boy: Frisch's has record sales
NS Group Inc. reports loss
Tristate Summary
What's the Buzz?
Bulk e-mail may grow from mail-handling fears
Postal Service to seek aid Congress
Disney asks workers to cut back jobs
Leading indicators nosedive
Lexmark to cut as many as 1,600 jobs
Morning Memo
Tank maker, union reach deal to end strike